Resources Repository
-
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Global | Priority Setting/Ethics | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
Teaching PackPublication, Teaching Resource 2022Teaching Pack: Extended Cost-Effectiveness Analysis
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended …
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended cost-effectiveness analysis (ECEA) and detailing how it is conducted, and assembles ECEA publications and teaching materials. In addition to the videos, this teaching pack includes a glossary and tutorial. Videos include: Video 1. Introduction to ECEA (~2 min) Video 2. Quantifying Health Benefits (~4 min) Video 3. Private Expenditures Averted (~3 min) Video 4. Financial Risk Protection (~5 min) Video 5.…
Global | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine -
ArticlePublication 2019Systematic Review of Economic Evaluations of Vaccination Strategies Against Tuberculosis
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited …
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited and varies by age, so a valid cost-effectiveness study is needed to assist decision-makers in the implementation of cost-effective strategies for BCG vaccination. Using the Quality of Health Economic Studies (QHES) instrument, the authors assessed the quality of published studies involving economic evaluations of BCG vaccination strategies in a variety of regions, target populations, and vaccine types. Most of the…
Global | Evidence Synthesis | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
ArticlePublication 2019Decision-Making for Universal Access to Tuberculosis Diagnosis In India
The authors evaluated the costs of centralized and decentralized testing for tuberculosis with Xpert MTB/RIF …
The authors evaluated the costs of centralized and decentralized testing for tuberculosis with Xpert MTB/RIF (Xpert), a WHO-endorsed test. They used an agent-based simulation of TB transmission in a hypothetical representative region in India to assess the impact and cost-effectiveness of various strategies to provide universal access to diagnosis and drug susceptibility testing (DST) for tuberculosis. The authors found that decentralization was most favorable compared to centralized testing when volume at decentralized facilities was high,…
Asia & Pacific | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
ArticlePublication 2019POC Diagnosis of TB With Truenat Assay: CEA for India's Public Sector
Using a microsimulation model, the authors compared four TB diagnostic strategies for HIV-negative adults with …
Using a microsimulation model, the authors compared four TB diagnostic strategies for HIV-negative adults with presumptive TB in order to evaluate the potential cost-effectiveness of strategies that incorporate Truenat, a molecular assay that rapidly detects TB and rifampicin-resistance. They projected life expectancy, costs, incremental cost-effectiveness ratios (ICERs), and 5-year budget impact of deploying Truenat POC in India's public sector. Used at the point-of-care in India, Truenat for TB diagnosis should improve linkage-to-care, increase life expectancy,…
Asia & Pacific | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
ArticlePublication 2019Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan
This study investigates the feasibility and cost of hepatitis C virus (HCV) elimination in Pakistan …
This study investigates the feasibility and cost of hepatitis C virus (HCV) elimination in Pakistan using a decision analytical model and microsimulation techniques from 2015 to 2030. Various scenarios, including the status quo and seven elimination strategies, were evaluated based on Pakistan-specific variables. Main outcomes included trends in HCV prevalence, mortality, disability-adjusted life-years, and total costs of HCV care. Results suggest that to achieve HCV elimination by 2030, significant scale-up of testing and treatment is…
Asia & Pacific | Decision Analysis | Infectious Diseases | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2019Cost-Effectiveness of Latent TB Screening before Immigration to Low-Incidence Countries
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening …
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening for active infections, screening for latent TB infection before immigration is rare. The authors used discrete event simulation to evaluate the cost-effectiveness preimmigration latent TB infection screening for migrants to low-incidence countries. They calculated cost per quality-adjusted life-year gained for migrants from countries with different TB incidences. Their analysis when combined with research on sustainability, acceptability, and program implementation can…
Global | Mathematical Models | Dynamic Simulation | Cost-Effectiveness Analysis | Infectious Diseases | Government/Law | Health/Medicine -
ReportPublication 2019Reference Case Guidelines for BCA in Global Health and Development
The "Benefit‐Cost Analysis Reference Case: Principles, Methods, and Standards" project, with support from the Bill …
The "Benefit‐Cost Analysis Reference Case: Principles, Methods, and Standards" project, with support from the Bill & Melinda Gates Foundation, culminates in the final “Reference Case Guidelines for Benefit-Cost Analysis in Global Health and Development.” These guidelines aim to facilitate the utilization and effectiveness of benefit-cost analysis by providing clarity on essential concepts, aiding implementation, and suggesting default values for key parameters, along with options for standardized sensitivity analysis. Targeted at practitioners with economic evaluation expertise…
Global | Benefit-Cost Analysis | Health/Medicine -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Global | Evidence Synthesis | Cost-Effectiveness Analysis | Policy/Regulation | Health/Medicine